|
Solvonis Therapeutics PLC on Wednesday reported ‘positive progress’ on its European patent application for the Awkn-Sdn-14 programme. The London-based biotechnology company aiming to develop innovative treatments for mental health and substance use disorders is collaborating with Awakn Life Sciences Corp to develop next-generation medicine for the treatment of trauma-related mental health disorders. This includes conditions such as post-traumatic stress disorder, which affects around 13 million adults in the US and an estimated 20 million across the US, UK and other ‘key’ EU markets. The application to the European Patent Office underpins the intellectual property portfolio of Awkn-Sdn-14, and specifically covers key compound classes under preclinical development. Following the acceptance of the application, the patent is expected to proceed to grant, Solvonis noted. Patent approval is also being pursued in other areas, such as the US. ‘This positive news from the European Patent Office is a strong validation of the scientific and commercial potential of the AWKN-SDN-14 programme,’ said Chief Executive Officer Anthony Tennyson. ‘Robust intellectual property is a critical pillar of our and Awakn’s strategy, and this progress represents an important step forward as we continue to advance our pipeline toward clinical development across key markets.’ Shares in Solvonis were down 4.4% at 0.17 pence in London on Wednesday afternoon. The stock has fallen 28% over the past year. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
